Why invest in Hofseth BioCare?

A strong ESG-profile, and patented processes coupled with world class R&D with diversified pipelines including research programs on asthma, COVID-19 and gastro

Ticker: HBC
Last updated: 14.08.2020 16:15
Latest

8.80 NOK

Change

0.02

Change (%)

0.23

Share information

IR contact

News

Reports

Governance

OVI 3832 01
LATEST REPORT

Q1 2020 Report

Download our latest report, or view all quarterly and yearly reports in the archives.

Download Q1 2020
All reports
16:9
NEXT UP

Financial calendar

Half yearly report 2020
28.08.2020

Q3 Quarterly report 2020
30.10.2020

Q4 Quarterly report 2020
05.02.2021

Stock exchange notices

View all notices

CORRECTION: SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

12.08.2020

SHARE CAPITAL DECREASE REGISTERED – NEW PAR VALUE

12.08.2020

HBC starts its accelerated COVID-19 Phase 2 clinical trial of OmeGo® salmon oil to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration

30.06.2020

HBC has begun protocol development for its accelerated Phase 2 clinical trial with OmeGo® to decrease Acute Respiratory Distress Syndrome and the need for assisted respiration in COVID-19 patients

26.05.2020

Completed Annual General Meeting

25.05.2020

Contact investor relations

James Berger
James Berger
Head of Investor Relations & Strategy
+41 79 950 10 34 jb@hofsethbiocare.no
Crawford Currie
Dr. Crawford Currie
Medical R&D & Investor Relations
+44 7968 195497 cc@hofsethbiocare.no